CryoLife (NYSE: CRY) and Antares Pharma (NASDAQ:ATRS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Valuation and Earnings

This table compares CryoLife and Antares Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
CryoLife $180.38 million 3.53 $10.77 million $0.28 68.04
Antares Pharma $52.22 million 5.63 -$24.33 million ($0.12) -15.67

CryoLife has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

CryoLife has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Profitability

This table compares CryoLife and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CryoLife 5.28% 6.43% 4.33%
Antares Pharma -34.27% -41.37% -25.74%

Insider and Institutional Ownership

69.0% of CryoLife shares are held by institutional investors. Comparatively, 36.8% of Antares Pharma shares are held by institutional investors. 6.0% of CryoLife shares are held by insiders. Comparatively, 11.6% of Antares Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for CryoLife and Antares Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CryoLife 0 0 4 0 3.00
Antares Pharma 0 0 3 1 3.25

CryoLife presently has a consensus price target of $23.63, suggesting a potential upside of 24.02%. Antares Pharma has a consensus price target of $3.95, suggesting a potential upside of 110.11%. Given Antares Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe Antares Pharma is more favorable than CryoLife.

Summary

CryoLife beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

CryoLife Company Profile

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.